Probius
Probius is a deep-tech company pioneering Quantum Electrochemical Spectroscopy (QES), a novel bioanalytical platform that bridges biology and AI by creating digital twins of biological specimens. Their technology enables reagent-free, rapid detection and quantification of thousands of analytes from minimal sample volumes, facilitating high-dimensional phenotypic signatures for biomedical research, drug development, and decentralized predictive healthcare. Probius offers a simple, scalable workflow with applications in biomarker discovery, pre-clinical models, and bioproduction quality control, positioning itself as a transformative player in bioanalytics with significant market potential across pharmaceuticals, biotechnology, and healthcare sectors.
Probius
Probius is a deep-tech company pioneering Quantum Electrochemical Spectroscopy (QES), a novel bioanalytical platform that bridges biology and AI by creating digital twins of biological specimens. Their technology enables reagent-free, rapid detection and quantification of thousands of analytes from minimal sample volumes, facilitating high-dimensional phenotypic signatures for biomedical research, drug development, and decentralized predictive healthcare. Probius offers a simple, scalable workflow with applications in biomarker discovery, pre-clinical models, and bioproduction quality control, positioning itself as a transformative player in bioanalytics with significant market potential across pharmaceuticals, biotechnology, and healthcare sectors.
TL;DR
Core technology: Quantum Electrochemical Spectroscopy (QES): reagent-/label-free electrochemical sensing that produces cloud-stored "digital twin" signatures of biological samples
Use cases: High-dimensional phenotypic signatures for biomarker discovery, multiplex bioanalysis, preclinical models, bioproduction QC, and decentralized/predictive healthcare
Funding snapshot: Company states ~ $11M dilutive funding plus $5M non-dilutive; press materials cite an $8M Series A (Cota Capital, 2022) and Crunchbase lists a Seed round (UCeed, 2023)
Founding & HQ: Founded 2016; headquartered in Fremont, California
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Bioanalytics and high-dimensional phenotypic data generation to support biomedical research, drug development, and decentralized healthcare.
Founded
2016
Industry
Biotechnology
Tech Stack
Funding Track Record
$8M
Described in company press materials as an $8M Series A led by Cota Capital.
undisclosed
Listed on Crunchbase as a Seed round from UCeed with the amount not publicly disclosed.
Investor Signal
“Cota Capital is cited as the lead investor for an $8M Series A (2022). Other investors named by the company include Zoic Capital, Baidu Ventures, Stanford, Shanda Group, UCeed, Bill & Melinda Gates Foundation, and Propel(X).”